Blueprint Medicines Corporation Stock Earnings Report
Current P/E ratio: -4.34 | Price (May 26, 2023, EOD): $57.75 (Find current average P/E ratios for all sectors below)
BPMC Upcoming Earnings (Q2 2023)
|Earnings Date:||Jul 31, 2023|
BPMC Analysts Price TargetsCurrently no data available.
About Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Last 3 Quarters for BPMC Premium
Below you can see how BPMC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Average Sector P/E ratio
Is your stock priced above or below the average P/E ratio?
A higher P/E ratio shows that investors are willing to pay a higher share price today because of growth expectations in the future. For example, a company with a current P/E of 25, trades at 25 times today's earnings.
|Name||Number of firms||Average PE|
|Auto & Truck||13||15|
|Bank (Money Center)||7||11|
|Brokerage & Investment Banking||39||14|
|Business & Consumer Services||165||32|
|Coal & Related Energy||22||7|
|Electronics (Consumer & Office)||20||18|
|Environmental & Waste Services||82||70|
|Financial Svcs. (Non-bank & Insurance)||232||36|
|Green & Renewable Energy||22||88|
|Healthcare Support Services||128||131|
|Heathcare Information and Technology||129||132|
|Investments & Asset Management||192||120|
|Metals & Mining||92||37|
|Office Equipment & Services||22||16|
|Oil/Gas (Production and Exploration)||269||19|
|Packaging & Container||24||43|
|Publishing & Newspapers||31||28|
|Real Estate (Development)||20||146|
|Real Estate (General/Diversified)||12||31|
|Real Estate (Operations & Services)||57||23|
|Retail (Building Supply)||17||202|
|Retail (Grocery and Food)||13||38|
|Retail (Special Lines)||89||25|
|Shipbuilding & Marine||10||30|
|Software (System & Application)||363||144|
|Total Market (without financials)||5878||62|
Updated: Jan 2020
About Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally avail... BPMC Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.